Cost-Effectiveness of Cetuximab, Cetuximab Plus Irinotecan, and Panitumumab for Third and Further Lines of Treatment for KRAS Wild-Type Patients with Metastatic Colorectal Cancer

Author:

Hoyle Martin,Peters Jaime,Crathorne Louise,Jones-Hughes Tracey,Cooper Chris,Napier Mark,Hyde Chris

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference27 articles.

1. Cancer Research UK. CancerStats key facts: large bowel cancer (colorectal cancer). 2011. Available from: http://info.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@sta/documents/generalcontent/crukmig_1000ast-2806.pdf. [Accessed December 18, 2012]

2. Aravani A., Thomas J., Day M., et al. Survival by stage of colorectal cancer in England. Northern and Yorkshire Cancer Registry and Information Service. Available from: http://www.nycris.nhs.uk/uploads/doc/vid_6573_Colorectal%20survval%20by%20stage-%20A.Aravani3%20rtg%202c.pdf, 2009. [Accessed November 16, 2012].

3. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment;Grothey;J Clin Oncol,2004

4. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer;Van Cutsem;J Clin Oncol,2007

5. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial;Mittmann;J Natl Cancer Inst,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3